常用名索格列净英文名LX-4211
CAS号1018899-04-1分子量424.938
密度1.4±0.1 g/cm3沸点607.9±55.0 °C at 760 mmHg
分子式C21H25ClO5S熔点N/A
MSDSN/A闪点321.4±31.5 °C
| 中文名 | (2S,3R,4R,5S,6R)-2-(4-氯-3-(4-乙氧基苄基)苯基)-6-(甲基硫代)四氢-2H-吡喃-3,4,5-三醇 |
|---|---|
| 英文名 | (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol |
| 中文别名 | 索格列净 |
| 英文别名 | 更多 |
| 描述 | LX-4211是SGLT1/2抑制剂，是抗糖尿病剂。 |
|---|---|
| 相关类别 | 信号通路 >> 跨膜转运 >> SGLT 研究领域 >> 代谢疾病 |
| 参考文献 | [1]. Zambrowicz B, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69. [2]. Powell DR, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013 May;345(2):250-9. |
| 密度 | 1.4±0.1 g/cm3 |
|---|---|
| 沸点 | 607.9±55.0 °C at 760 mmHg |
| 分子式 | C21H25ClO5S |
| 分子量 | 424.938 |
| 闪点 | 321.4±31.5 °C |
| 精确质量 | 424.111115 |
| PSA | 104.45000 |
| LogP | 5.63 |
| 蒸汽压 | 0.0±1.8 mmHg at 25°C |
| 折射率 | 1.642 |
| sotagliflozin |
| LP-802034 |
| (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methylsulfanyl-tetrahydro-pyran-3,4,5-triol |
| β-L-Xylopyranoside, methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-, (5S)- |
| LX-4211 |
| (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol |
| LX4211 |
| CS-1069 |
| LX 4211 |
| Methyl (5S)-5-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1-thio-β-L-xylopyranoside |
| UNII-6B4ZBS263Y |
